<div class="article-table-content" id="art40511-tbl-0001">
            <header class="article-table-caption"><span class="table-caption__label">Table 1.
            </span>Baseline characteristics of the patients with SLE treated with placebo or belimumab<a class="noteLink scrollableLink" title="Link to note" id="art40511-note-0005_22-controller" href="#art40511-note-0005_22" aria-controls="art40511-note-0005_22" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">a</a><div class="footNotePopup" id="art40511-note-0005_22" aria-labelledby="art40511-note-0005_22-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span><span><sup><i>a</i></sup></span>
                     SLE = systemic lupus erythematosus; SC = 
subcutaneous; PGA = physician's global assessment of disease activity; 
FACIT‐Fatigue = Functional Assessment of Chronic Illness 
Therapy–Fatigue.
                     <br></span><span class="chevronDown"></span>
</div>
            </header><div class="article-table-content-wrapper">
               <table class="table article-section__table">
<thead><tr>
<th class="bottom-bordered-cell right-bordered-cell left-aligned"></th>
                        
                        <th class="bottom-bordered-cell center-aligned">Placebo (n = 108)</th>
                        
                        <th class="bottom-bordered-cell center-aligned">SC belimumab 200 mg (n = 248)</th>
                        
                     </tr></thead>
<tbody>
<tr>
<td class="right-bordered-cell left-aligned">Women, no. (%)</td>
                        
                        <td class="center-aligned">106 (98.1)</td>
                        
                        <td class="center-aligned">236 (95.2)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">Age, mean ± SD years</td>
                        
                        <td class="center-aligned">34.6 ± 10.38</td>
                        
                        <td class="center-aligned">34.6 ± 10.96</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">Weight, mean ± SD kg</td>
                        
                        <td class="center-aligned">64.9 ± 17.86</td>
                        
                        <td class="center-aligned">64.5 ± 16.30</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">Enrollment by region, no. (%)</td>
                        
                        <td class="left-aligned"></td>
                        
                        <td class="left-aligned"></td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">US</td>
                        
                        <td class="center-aligned">24 (22.2)</td>
                        
                        <td class="center-aligned">55 (22.2)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Americas excluding US</td>
                        
                        <td class="center-aligned">21 (19.4)</td>
                        
                        <td class="center-aligned">52 (21.0)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Western Europe/Australia/Israel</td>
                        
                        <td class="center-aligned">6 (5.6)</td>
                        
                        <td class="center-aligned">24 (9.7)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Eastern Europe</td>
                        
                        <td class="center-aligned">24 (22.2)</td>
                        
                        <td class="center-aligned">58 (23.4)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Asia</td>
                        
                        <td class="center-aligned">33 (30.6)</td>
                        
                        <td class="center-aligned">59 (23.8)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">Ethnicity, no. (%)</td>
                        
                        <td class="left-aligned"></td>
                        
                        <td class="left-aligned"></td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Hispanic or Latino</td>
                        
                        <td class="center-aligned">33 (30.6)</td>
                        
                        <td class="center-aligned">70 (28.2)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Not Hispanic or Latino</td>
                        
                        <td class="center-aligned">75 (69.4)</td>
                        
                        <td class="center-aligned">178 (71.8)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">Race, no. (%)</td>
                        
                        <td class="left-aligned"></td>
                        
                        <td class="left-aligned"></td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">White</td>
                        
                        <td class="center-aligned">58 (53.7)</td>
                        
                        <td class="center-aligned">140 (56.5)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Asian</td>
                        
                        <td class="center-aligned">32 (29.6)</td>
                        
                        <td class="center-aligned">63 (25.4)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">African American/African heritage</td>
                        
                        <td class="center-aligned">7 (6.5)</td>
                        
                        <td class="center-aligned">26 (10.5)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Other</td>
                        
                        <td class="center-aligned">13 (12.0)</td>
                        
                        <td class="center-aligned">23 (9.3)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">Disease duration, median (range) years</td>
                        
                        <td class="center-aligned">4.0 (0–32)</td>
                        
                        <td class="center-aligned">5.1 (0–35)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">SELENA–SLEDAI score, mean ± SD<a class="noteLink scrollableLink" title="Link to note" id="art40511-note-0006_23-controller" href="#art40511-note-0006_23" aria-controls="art40511-note-0006_23" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">b</a><div class="footNotePopup" id="art40511-note-0006_23" aria-labelledby="art40511-note-0006_23-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span><span><sup><i>b</i></sup></span>
                                 Patients were required to have a score 
of ≥8 on the Safety of Estrogens in Lupus Erythematosus National 
Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI) at screening (occurring within 35 days prior to 
baseline).
                                 <br></span><span class="chevronDown"></span>
</div>
                        </td>
                        
                        <td class="center-aligned">11.7 ± 3.14</td>
                        
                        <td class="center-aligned">11.5 ± 3.31</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">SELENA–SLEDAI score, no. (%)<a class="noteLink scrollableLink" title="Link to note" id="art40511-note-0006_24-controller" href="#art40511-note-0006_24" aria-controls="art40511-note-0006_24" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">b</a><div class="footNotePopup" id="art40511-note-0006_24" aria-labelledby="art40511-note-0006_24-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span><span><sup><i>b</i></sup></span>
                                 Patients were required to have a score 
of ≥8 on the Safety of Estrogens in Lupus Erythematosus National 
Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI) at screening (occurring within 35 days prior to 
baseline).
                                 <br></span><span class="chevronDown"></span>
</div>
                        </td>
                        
                        <td class="left-aligned"></td>
                        
                        <td class="left-aligned"></td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">≤9</td>
                        
                        <td class="center-aligned">30 (27.8)</td>
                        
                        <td class="center-aligned">62 (25.0)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">≥10</td>
                        
                        <td class="center-aligned">78 (72.2)</td>
                        
                        <td class="center-aligned">186 (75.0)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">SELENA–SLEDAI organ involvement, no. (%)</td>
                        
                        <td class="left-aligned"></td>
                        
                        <td class="left-aligned"></td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Mucocutaneous</td>
                        
                        <td class="center-aligned">91 (84.3)</td>
                        
                        <td class="center-aligned">205 (82.7)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Musculoskeletal</td>
                        
                        <td class="center-aligned">72 (66.7)</td>
                        
                        <td class="center-aligned">184 (74.2)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Immunologic</td>
                        
                        <td class="center-aligned">108 (100.0)</td>
                        
                        <td class="center-aligned">248 (100.0)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Renal</td>
                        
                        <td class="center-aligned">26 (24.1)</td>
                        
                        <td class="center-aligned">38 (15.3)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Hematologic</td>
                        
                        <td class="center-aligned">13 (12.0)</td>
                        
                        <td class="center-aligned">23 (9.3)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Vascular</td>
                        
                        <td class="center-aligned">4 (3.7)</td>
                        
                        <td class="center-aligned">14 (5.6)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Cardiovascular and respiratory</td>
                        
                        <td class="center-aligned">6 (5.6)</td>
                        
                        <td class="center-aligned">16 (6.5)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">≥1 flare, no. (%)<a class="noteLink scrollableLink" title="Link to note" id="art40511-note-0007_25-controller" href="#art40511-note-0007_25" aria-controls="art40511-note-0007_25" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">c</a><div class="footNotePopup" id="art40511-note-0007_25" aria-labelledby="art40511-note-0007_25-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span><span><sup><i>c</i></sup></span>
                                 During the screening period (day −35 to day 0).
                                 <br></span><span class="chevronDown"></span>
</div>
                        </td>
                        
                        <td class="center-aligned">24 (22.2)</td>
                        
                        <td class="center-aligned">48 (19.4)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">≥1 severe flare, no. (%)<a class="noteLink scrollableLink" title="Link to note" id="art40511-note-0007_26-controller" href="#art40511-note-0007_26" aria-controls="art40511-note-0007_26" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">c</a><div class="footNotePopup" id="art40511-note-0007_26" aria-labelledby="art40511-note-0007_26-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span><span><sup><i>c</i></sup></span>
                                 During the screening period (day −35 to day 0).
                                 <br></span><span class="chevronDown"></span>
</div>
                        </td>
                        
                        <td class="center-aligned">1 (0.9)</td>
                        
                        <td class="center-aligned">5 (2.0)</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">PGA, mean ± SD</td>
                        
                        <td class="center-aligned">1.57 ± 0.457</td>
                        
                        <td class="center-aligned">1.59 ± 0.434</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">FACIT‐Fatigue, mean ± SD</td>
                        
                        <td class="center-aligned">33.4 ± 10.82</td>
                        
                        <td class="center-aligned">34.0 ± 11.75</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">Medications</td>
                        
                        <td class="left-aligned"></td>
                        
                        <td class="left-aligned"></td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Any corticosteroid, no. (%)</td>
                        
                        <td class="center-aligned">99 (91.7)</td>
                        
                        <td class="center-aligned">231 (93.1)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Corticosteroid dosage, mean ± SD mg/day<a class="noteLink scrollableLink" title="Link to note" id="art40511-note-0008_27-controller" href="#art40511-note-0008_27" aria-controls="art40511-note-0008_27" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">d</a><div class="footNotePopup" id="art40511-note-0008_27" aria-labelledby="art40511-note-0008_27-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span><span><sup><i>d</i></sup></span>
                                 Prednisone equivalent.
                                 <br></span><span class="chevronDown"></span>
</div>
                        </td>
                        
                        <td class="center-aligned">11.4 ± 7.39</td>
                        
                        <td class="center-aligned">12.2 ± 8.34</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Corticosteroid dosage, no. (%)</td>
                        
                        <td class="left-aligned"></td>
                        
                        <td class="left-aligned"></td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">0 mg/day</td>
                        
                        <td class="center-aligned">9 (8.3)</td>
                        
                        <td class="center-aligned">17 (6.9)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">&gt;0 to ≤7.5 mg/day</td>
                        
                        <td class="center-aligned">29 (26.9)</td>
                        
                        <td class="center-aligned">67 (27.0)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">&gt;7.5 mg/day</td>
                        
                        <td class="center-aligned">70 (64.8)</td>
                        
                        <td class="center-aligned">164 (66.1)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Any antimalarial, no. (%)</td>
                        
                        <td class="center-aligned">68 (63.0)</td>
                        
                        <td class="center-aligned">177 (71.4)</td>
                        
                     </tr>
<tr>
<td style="padding-left:2em;" class="right-bordered-cell left-aligned">Any immunosuppressant, no. (%)</td>
                        
                        <td class="center-aligned">59 (54.6)</td>
                        
                        <td class="center-aligned">117 (47.2)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">Azathioprine</td>
                        
                        <td class="center-aligned">26 (24.1)</td>
                        
                        <td class="center-aligned">48 (19.4)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">Cyclosporine</td>
                        
                        <td class="center-aligned">2 (1.9)</td>
                        
                        <td class="center-aligned">4 (1.6)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">Cyclophosphamide</td>
                        
                        <td class="center-aligned">1 (0.9)</td>
                        
                        <td class="center-aligned">1 (0.4)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">Leflunomide</td>
                        
                        <td class="center-aligned">0</td>
                        
                        <td class="center-aligned">1 (0.4)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">Methotrexate</td>
                        
                        <td class="center-aligned">12 (11.1)</td>
                        
                        <td class="center-aligned">24 (9.7)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">Mizoribine</td>
                        
                        <td class="center-aligned">4 (3.7)</td>
                        
                        <td class="center-aligned">6 (2.4)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">Mycophenolate</td>
                        
                        <td class="center-aligned">16 (14.8)</td>
                        
                        <td class="center-aligned">35 (14.1)</td>
                        
                     </tr>
<tr>
<td style="padding-left:4em;" class="right-bordered-cell left-aligned">Tacrolimus</td>
                        
                        <td class="center-aligned">5 (4.6)</td>
                        
                        <td class="center-aligned">5 (2.0)</td>
                        
                     </tr>
</tbody>
</table>
</div>
            
            
            
            <div class="article-section__table-footnotes">
               <ul>
<li id="art40511-note-0005">
<span><sup><i>a</i></sup></span>
                     SLE = systemic lupus erythematosus; SC = 
subcutaneous; PGA = physician's global assessment of disease activity; 
FACIT‐Fatigue = Functional Assessment of Chronic Illness 
Therapy–Fatigue.
                     
                  </li>
                  <li id="art40511-note-0006">
<span><sup><i>b</i></sup></span>
                     Patients were required to have a score of ≥8 on the
 Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)
 version of the Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) at screening (occurring within 35 days prior to baseline).
                     
                  </li>
                  <li id="art40511-note-0007">
<span><sup><i>c</i></sup></span>
                     During the screening period (day −35 to day 0).
                     
                  </li>
                  <li id="art40511-note-0008">
<span><sup><i>d</i></sup></span>
                     Prednisone equivalent.
                     
                  </li>
               </ul>
</div>
            <div class="article-section__table-source"></div>
         </div>